Racura Oncology Ltd

Market Data

Latest Earnings

Appendix 4D & Half-Year Financial Statements

27 February 2026

Racura Oncology Limited (formerly Race Oncology Limited) reported a net loss of $4.1M for H1 FY26, swinging from a $0.5M profit in the prior corresponding period, driven by increased R&D spending and a $1.1M non-cash loss on extinguishment of bonus liabilities settled via share options. Excluding non-cash items (share-based payments and loss on extinguishment), the underlying operating loss was approximately $2.25M. The company significantly strengthened its cash position to $20.9M (up from $13.7M at 30 June 2025) through option exercises and a placement, providing a solid runway to advance multiple clinical programs. Key points: Cash position increased materially to $20.9M at 31 December 2025 (from $13.7M at 30 June 2025), providing a strong runway for clinical programs.; Raised ~$9.5M in financing activities during the half via option exercises ($6.2M cash proceeds) and a placement ($3.2M), demonstrating continued investor support.; Received $2.78M R&D Tax Incentive from the ATO for FY2025, providing meaningful non-dilutive funding.